Hunter Perkins Capital Management, LLC Prothena Corp Public LTD CO Transaction History

Hunter Perkins Capital Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 13, 2022	BUY	$25.16 - $60.63 $103,181 - $248,643	4,101 New	4,101 $249,000
Q4 2021 Jan 27, 2022	SELL	$42.11 - $73.26 $173,240 - $301,391	-4,114 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$48.2 - $78.89 $81,265 - $133,008	-1,686 Reduced 29.07%	4,114 $293,000
Q2 2021 Jul 30, 2021	BUY	$21.63 - $57.65 $125,454 - $334,370	5,800 New	5,800 $298,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $641M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Hunter Perkins Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Hunter Perkins Capital Management, LLC with notifications on news.